Continued strong performance during the second quarter

Significant events during the quarter

• Mentice has received a significant repeat order for simulation solutions of approximately 2.4 MUSD, corresponding to approximately 26.0 MSEK from a leading global medical technology company in the USA.
• Siemens Healthineers and Mentice announced that the collaboration in China, previously focused on Siemens Robotics (Corindus), has been transitioned and enhanced to a general collaboration around innovation and education for the Chinese market.
• Mentice´s CFO, Gunilla Andersson, resigned at her own request for new challenges outside the company. During the month of June, Mentice appointed Henrik Hang as interim CFO. Henrik has been in the company since mid-June and will formally take over the CFO position as interim CFO on July 21st. Gunilla will remain in the company as support up to her last day in mid-august.

SECOND QUARTER (APRIL– JUNE 2022)

• Order intake amounted to 77.4 (57.3) MSEK, an increase of 35.1%.
• Order book by the end of the period was 125.3 (108.9) MSEK, whereof 54.2 MSEK is expected as revenue in 2023.
• Net sales amounted to 74.3 (45.1) MSEK, an increase of 64.7 %, whereof 54.1% is organic.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 10.7 (-12.2) MSEK.
• Net income for the period amounted to 1.5 (-17.6) MSEK.
• Earnings per share (EPS) were 0.06 (-0.71) SEK.
• Cash flow from operating activities totaled 5.2 (-18.3) MSEK.

FIRST HALF YEAR (JANUARY – JUNE 2022)

• Order intake amounted to 135.1 (111.7) MSEK, an increase of 20.9%.
• Order book by the end of the period was 125.3 (108.9) MSEK, whereof 54.2 MSEK is expected as revenue in 2023.
• Net sales amounted to 139.3 (98.2) MSEK, an increase of 41.8 %, whereof 33.6 % is organic.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 17.9 (-13.5) MSEK.
• Net income for the period amounted to 0.0 (-25.1) MSEK.
• Earnings per share (EPS) were 0.00 (-1.01) SEK.
• Cash flow from operating activities totaled 2.5 (-7.0) MSEK.

Webcast presentation of the interim report
To register for the presentation, please visit https://investor.mentice.com/

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-20 08:30 CEST.

Attachments
Q2 Report EN 23 Final